Compare MakeMyTrip Ltd (MMYT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Organon & Co. Common Stock — how do they compare? MakeMyTrip Ltd trades at $43.7 (market cap $4.21B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: MakeMyTrip Ltd is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Organon & Co. Common Stock for 0 Days on average.
| MMYT | OGN | |
|---|---|---|
Market Cap | $4.21B | $3.62B |
Volume | 954,905 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.73 | $13.81 |
52-Week Low | $36.30 | $5.70 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $4.87B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $44.70, showing modest daily gains of 0.81%. The stock faces bearish technical signals with mixed earnings performance - beating Q1 2026 estimates but missing Q4 2025 and Q2 2026. Revenue growth remains positive with $978M in 2025, though profitability metrics show volatility. Analyst sentiment remains strongly bullish with a $77 consensus target representing 72% upside potential.
The stock presents significant upside based on analyst targets but faces execution risks amid volatile earnings and rising debt levels. Key catalysts include the planned Indian listing and operational resilience, while risks include geopolitical disruptions and competitive pressures in the travel sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
